*Please note, the 2022 application portal has been closed and no more applications will be accepted.
Read the NETRF 2022 Award Program Guidelines
NETRF’s grant process
The Neuroendocrine Tumor Research Foundation (NETRF) grant application model employs a 2-step process. Funding is only granted to applicants completing both steps.
- Applicants interested in a 2022 award must submit a competitive letter of intent (LOI) by 5:00 PM (ET), March 7, 2022. (One LOI per applicant, per award type, may be submitted.)
The LOIs allow NETRF to identify projects with the greatest scientific potential without requiring applicants first to submit a lengthy full application. A limited number of applicants whose LOI is deemed most meritorious will move to the 2nd step and will be invited to submit a full proposal.
- By June 2022, a limited number of LOI authors will be invited to submit full proposals for consideration by the NETRF Board of Scientific Advisors and external reviewers. Full proposals are due in the fall. Grant awards will be announced at the end of the year.
Learn more about the grant review process. Sign up to be notified of future NETRF grant announcements.
Be notified of grant opportunities
NETRF awarded six new research grants totaling $1.85 million to leading academic institutions around the world. The goal of the funding is to improve current treatments for neuroendocrine tumors (NETs), an uncommon and poorly understood cancer, which occurs in the body’s hormone-producing cells.
John Kanki, PhD, has joined Neuroendocrine Tumor Research Foundation (NETRF) as Director of Research. In
New grants to explore CAR-T, PRRT, a vaccine for NETs and other innovative approaches.